James “Jamie” Topper is the managing director of Frazier Healthcare Partners‘ Life Sciences team. Known as a “junkie for good science and smart people,” according to Forbes, he was a co-founder of Calistoga Pharmaceuticals, which was acquired by Gilead, and was involved in a Series A funding round for Acerta Pharma, which was bought for $7 billion.
He has invested across over 20 companies in the life sciences and biopharmaceutical sector. Throughout his career with Frazier, Jamie has led and served on the board of several companies in the life sciences, such as Rempex, Incline, Alnara, Portola, CoTherix, Threshold, Allena Pharmaceuticals, Alpine Immune Sciences, Amunix, AnaptysBio, Aptinyx and Mavupharma.
He ranked on the Forbes’ Midas List in 2011 and 2016 and has been recognised by the publication as a top 10 investor in healthcare.
Prior to his career in investing, Jamie was the head of cardiovascular research and development at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics) and the vice president of Biology at COR Therapeutics. He also served on the medical school faculties at Stanford and Harvard Medical Schools and has authored over 50 publications.
Jamie received his bachelor’s from the University of Michigan and his medical degree and PhD in biophysics from Stanford.Tags: biotechnology, Medicine, VC